SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (23101)7/13/1998 12:40:00 PM
From: WTDEC  Read Replies (6) | Respond to of 32384
 
Henry, the fact that the FDA is giving priority review should be seen as a huge boost to LGND's credibility. We were told this Spring that the Panretin filing delay might not result in any delay in getting Panretin to those who it can help. Skepticism was widespread but it is quite believable now. LGND is to be congratulated for reading the situation correctly.

Now we need the response to the FDA for ONTAK.

Regards,

Walter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News